Can chemical regulators fnd new ways of applying artifcial intelligence to regulatory risk assessment? Cashing in on biomedicine’s bonanza

摘要

Biomedicine has benefted enormously from ‘omics’ data, with reams of information being generated on genetics (genomics and transcriptomics), proteins (proteomics) and metabolites (metabolomics). Now chemical regulators are looking at ways to apply the same techniques to regulatory risk assessment, aided by advances in machine learning and artifcial intelligence (AI).